You should consider shares of Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and ImmunoGen Inc. (NASDAQ:IMGN) if you are looking for a great stocks to invest in. Starting with the PTLA shares, which traded at $14.90 at the close of the recent session, gaining 4.27%. On Wednesday, the company’s shares shed $0.61 from its value which represented in intraday trading. The stock is now -37.60% lower in year-to-date (YTD) trading. PTLA’s intraday high was $14.925 while its lowest price touched $14.15. The stock’s 52-week high price is $37.95, which means the current price is at -60.74%. In terms of trading activity, the daily trading volume rose to 2279307 against 200-day average trading volume of 1,118,592 shares.
What are analyst forecasts for Portola Pharmaceuticals Inc. (NASDAQ:PTLA)?
At a consensus rating of 4.20, PTLA is trending as a streaking Moderate Buy, as it has been the case a month ago when 5 analysts called it a Strong Buy. Two months ago, 5 analysts recommended, on average, that PTLA stock is a Strong Buy. The Healthcare company’s shares’ overall bullish trend saw it close higher on Wednesday compared to its opening price of $14.29 on the day.
Forecasts for Portola Pharmaceuticals Inc. (NASDAQ:PTLA) give the stock a fair value for the growth from its last price.
Portola Pharmaceuticals Inc. (NASDAQ:PTLA) Upgrades and Downgrades
In terms of rating changes, Oppenheimer on January 10, 2020, Downgrade Portola Pharmaceuticals Inc. (PTLA) at Perform. Analysts at Goldman have assigned a Neutral rating for the stock in their research note on November 08, 2019 with an estimated price target of $35. Moreover, Credit Suisse analysts issued a rating of Neutral for the stock on August 05, 2019, giving it a price target of $35 for the next 12 months. On July 10, 2019, the stock earned a Neutral rating due to an analyst call from Credit Suisse, while analysts from Credit Suisse on August 27, 2018 suggested that the stock is Neutral.
ImmunoGen Inc. (NASDAQ:IMGN) adds $0.36 on Wednesday
The IMGN stock has tanked -3.04% year-to-date and is currently trading at $4.95, which is -19.18% below its 52-week high. The company shares gained 7.84% on the day and have risen nearly 181.25% off a low hit. At current levels, ImmunoGen Inc. has a valuation of about $50.80M. As of 01/15/20, this stock has fallen -0.40% during the week and closed at $4.59 in the previous session. However, recent ImmunoGen Inc. stock performance shows that IMGN shares are 38.27% up over the last month, and 102.87% up for the last three months.
Earnings per share (EPS) estimates for the current quarter are -$0.32, with the trailing 12-month share earnings at -$1.02. The ratio is expected to be up by 35.00% for the current year 2019 and 20.50% for next year. But will the IMGN stock surprise in the current quarter results, where the -$0.15 actual EPS reported on 9/29/2019 surprised by 16.70% or was higher by $0.03 from the estimated -$0.18.
Sales Growth to decline -38.90% for the year
How well will ImmunoGen Inc. perform as a business over the current quarter, year and next 5-year period? Compared to the year-ago quarter, analysts forecast the company to bring in between $27M and $31.7M in current quarter sales. The consensus estimated for the current quarter is $29.42M from sales. Forecasts for this fiscal year are between $64.4M and $69.1M and the consensus estimate for sales is at $66.89M. IMGN has its next quarter sales estimates at between $9M and $13.86M, with the quarter-over-quarter growth estimates at 10.70% and the annual growth forecast for the year at -38.90%.
Who owns shares in ImmunoGen Inc. (IMGN)?
Let’s briefly focus on the share ownership of the ImmunoGen Inc. (NASDAQ:IMGN) stock, where we find that 70.70% of shares are held by institutions. Redmile Group, LLC tops the list of institutional owners as it is holding 14.62 million shares or 9.76% of shares outstanding. Vanguard Group, Inc. (The) and Blackrock Inc. held 13.94 million and 12.09 million representing 9.31% and 8.08% respectively at the close of the last trading session. As of Sep 29, 2019, ClearBridge Investments, LLC accounted for 10.36 million shares at over 25.08 million. This represented 6.92% of shares outstanding. Renaissance Technologies, LLC held 8.52 million shares at over 20.63 million representing 5.69% of shares outstanding.